Paul M. Scola PhD

Dr. Scola received his Ph.D. in organic chemistry from The Pennsylvania State University where he conducted research under the guidance of Professor Steven Weinreb. He then assumed a postdoctoral position at Harvard University under the tutelage of Professor Yoshito Kishi. Paul joined Bristol-Myers Squibb in 1992, where he is currently a Director in the department of Discovery Chemistry and Molecular Technologies. The focus of Paul’s research efforts includes the discovery of small molecule antiviral agents for the treatment of hepatitis C virus (HCV) infection. As part of that effort, Paul had the privilege of co-chairing the HCV NS3 protease inhibitor team which discovered BMS-650032 (asunaprevir), an approved treatment for HCV that is administered as a dual cocktail with BMS’ daclatasvir. More recently, Paul has co-led full-phase discovery teams in Immuno-Oncology. An important outcome of the team’s effort was the discovery of BMS-986189, a macrocyclic peptide that is a potent inhibitor of PD-L1 and has progressed to the clinical stage.